-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 FWEpRbqu8aQX047VYWACgxyeCYsOOwJaOn1HhnLPkYZEvKRaa6j2U7uaTK6+dtbc
 AbvvFnHx3LHNWEyZ5El4xA==

<SEC-DOCUMENT>0001144204-06-052289.txt : 20061212
<SEC-HEADER>0001144204-06-052289.hdr.sgml : 20061212
<ACCEPTANCE-DATETIME>20061212171529
ACCESSION NUMBER:		0001144204-06-052289
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20061212
FILED AS OF DATE:		20061212
DATE AS OF CHANGE:		20061212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		061272331

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT WEIZMANN BUILDING 3
		CITY:			REHOVOT76100 ISRAEL
		STATE:			L3

	MAIL ADDRESS:	
		STREET 1:		KIRYAT WEIZMANN BUILDING 3
		CITY:			REHOVOT76100 ISRAEL
		STATE:			L3
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v060197_6k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
      of Foreign Private Issuer</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Rule 13a-16 or 15d-16</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      the Securities Exchange Act of 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      December 12, 2006</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>XTL
      Biopharmaceuticals Ltd.</u></strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant's name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>750
      Lexington Avenue, 20</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong>th</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
      Floor</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>New
      York, New York 10022</u></strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="white">
            <td width="33%">&#160;</td>
            <td width="33%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font size="2">Form
                20-F <font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
                Form 40-F <font style="FONT-FAMILY: Wingdings">o</font></font></div>
            </td>
            <td width="33%">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td width="33%">&#160;</td>
            <td width="33%">&#160;</td>
            <td width="33%">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1): <font style="FONT-FAMILY: Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7): <font style="FONT-FAMILY: Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether by furnishing the information contained in this Form,
      the
      registrant is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="white">
            <td width="25%">&#160;</td>
            <td width="25%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font size="2">Yes
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
                No <font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font></div>
            </td>
            <td width="25%">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td width="25%">&#160;</td>
            <td width="25%">&#160;</td>
            <td width="25%">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      N/A
</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br>&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><img src="xtl_logo.jpg" alt=""></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
      BIOPHARMACEUTICALS TO PRESENT AT THE NYSSA 10TH ANNUAL BIOTECH/SPECIALTY PHARMA
      INDUSTRY CONFERENCE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NEW
      YORK, NEW YORK,</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>December
      12</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
      2006</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      - XTL
      Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) announced today
      that
      Ron Bentsur, the Company&#8217;s Chief Executive Officer, is scheduled to present at
      the NYSSA 10th Annual Biotech/Specialty Pharma Industry Conference. Mr.
      Bentsur&#8217;s presentation will take place tomorrow, Wednesday, December 13, 2006,
      at 3:10 pm EST at the New York Society of Security Analysts, 1177 Avenue of
      the
      Americas, 2nd Floor, in New York City. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      live
      webcast of Mr. Bentsur's presentation will be available at </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">http://investor.shareholder.com/media/eventdetail.cfm?eventid=32512&amp;CompanyID=XTLB&amp;e=1&amp;mediaKey=77339C30E2C20AA2E62897E0416D0684</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      An
      archived version of the webcast will be available following the conclusion
      of
      the live presentation.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
      XTL BIOPHARMACEUTICALS LTD.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      Biopharmaceuticals Ltd. (&#8220;XTL&#8221;) is engaged in the acquisition, development and
      commercialization of therapeutics for the treatment of infectious diseases,
      with
      a focus on hepatitis C. XTL is developing XTL-2125 - a small molecule,
      non-nucleoside inhibitor of the hepatitis C virus polymerase. XTL-2125 is
      currently in a Phase 1 clinical trial in patients with chronic hepatitis C.
      XTL
      is also developing XTL-6865 - a combination of two monoclonal antibodies against
      the hepatitis C virus - presently in Phase 1 clinical trials in patients with
      chronic hepatitis C. XTL&#8217;s hepatitis C pipeline also includes several families
      of pre-clinical hepatitis C small molecule inhibitors. &#160;XTL also has an
      active in-licensing and acquisition program designed to identify and acquire
      additional drug candidates. XTL is publicly traded on the NASDAQ, London, and
      Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Contact:</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      +1
      (212) 531 5960</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><strong>XTL
              BIOPHARMACEUTICALS LTD.</strong></font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:&#160;December
              12, 2006</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font size="2">/s/ Ron Bentsur</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%"><font size="2">Ron
              Bentsur</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Chief
              Executive Officer</font></td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br>&#160;</div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>xtl_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 xtl_logo.jpg
M_]C__@`(5T%.1S("_^``$$I&248``0$!`&``8```_]L`0P`0"PP.#`H0#@T.
M$A$0$Q@H&A@6%A@Q(R4=*#HS/3PY,S@W0$A<3D!$5T4W.%!M45=?8F=H9SY-
M<7EP9'A<96=C_]L`0P$1$A(8%1@O&AHO8T(X0F-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C_\``$0@`30#=`P$A
M``(1`0,1`?_$`!\```$%`0$!`0$!```````````!`@,$!08'"`D*"__$`+40
M``(!`P,"!`,%!00$```!?0$"`P`$$042(3%!!A-180<B<10R@9&A""-"L<$5
M4M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U155E=865IC
M9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2U
MMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$
M`!\!``,!`0$!`0$!`0$````````!`@,$!08'"`D*"__$`+41``(!`@0$`P0'
M!00$``$"=P`!`@,1!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6
M)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#
MQ,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:``P#`0`"$0,1
M`#\`]`HH`**`"B@`HH`**`"B@`HH`**`"B@`HH`**`"B@`HH`**`"B@`KRS7
M-9N-6NY&:1Q;!OW470`#."1_>P>3[^E=&'BFVS"O*RL=-X)UFXO&FL;N1YF1
M?,C=N3C."">_)&/Q]JZVLZL5&32+I2YHZA169H%%`!10`44`%%`!10`44`%%
M`!10`44`%%`!7$^,5U#3KM+FUO;M+:?.5$SX1^X]@1T'L>PK6C;FLS*K?ENC
M`MM>U2VN$F%]/)L.=DLC,K>Q!-=%?^&$UG;J>E7"*MU^\:.4\`G.[D9YSV]<
M\]JZ)M4VI)&$4ZB:;-".TM_"&B7,ZR>=</QN88#MSM`7/09)/.>M<3_;&I_]
M!&[_`._[?XTJ24[R:'4;A:*9TR+J5IX,NKVXO;@SS^6\9,Q)1-PQ@]B<G//3
M%<S_`&QJ?_01N_\`O^W^-5",97=NHIN4;*X?VQJ?_01N_P#O^W^-']L:G_T$
M;O\`[_M_C5\D>QGSR[A_;&I_]!&[_P"_[?XT?VQJ?_01N_\`O^W^-')'L'/+
MN']L:G_T$;O_`+_M_C7INDNTFD63R,6=H(RS,<DG:.36%>*25D;T9-MW9<HK
ME.DP;BXF6YE`FD`#D`!CZUO5T5DDE8\C+:DYSJ*3;LU^H45SGKE;4&9+.1E8
MJ1CD''<57TF223S?,=FQC&XY]:VBE[)L\NK4FL?"">EMNG4T:*Q/4"B@`HH`
M*JZE9)J.GSVDAPLJX!_NGJ#^!P::=G<35U8\IO+66RNY;:<8DB8J>#@^XSV/
M45U'@7562X;3)G)1P6A!_A8<D#CN,GTX]Z[JJYH7..F^692\9:JU[J;6L;G[
M/;';M[,XZGIVZ?AQUJ'PII!U/4U>10;:W(>7)'/7"X[Y(Y]LTE[E,'[]0]$O
M+2"^MGMKE-\3XW+DC.#GJ/<5F?\`"*:)_P`^7_D5_P#&N2-2459,ZI0C)W9A
M^+M$T[3=+BFL[?RY&F"$[V/&UCW/L*X^NRE)RC=G)5BHRLCTS_A%-$_Y\O\`
MR*_^-9GB/P]I=CH=S<VUKLE3;M;S&.,L!T)]#7/&K-R2;.B5*"BW8X:O6=%_
MY`EA_P!>\?\`Z"*TQ&R,Z&[+M%<AU'.W7_'U-_OM_.MZ6:.%=TKA1_.NJLF^
M5(\++JD:;K3F[)6_4KQZE;R'!+)Z;A5I65U#*P8'N#FL)TY0W/3P^+I8A>X]
M>W4&944LS!0.Y.*1)(Y,^6ZMCKM.:FSM<W=2"ER-Z]NH^H9;J"%MLD@!].O\
MJ<8N3LB:M:%&/-4=D11ZC;/U8H2<885;IS@X/4C#XJGB(W@PHJ#H"B@#DO&^
MC^=`NHVT698^)]HY9<<,?ICTZ'T%<0CM&ZO&Q5U(*LIP0?45W497A8XJJM(6
M&)[B>.&)=TDC!%&<9).!7JFBZ<NEZ9#:C&\#,C#^)CU/09]![`5&(EHD706K
M9?HKD.HYCQ]_R!(?^OA?_06K@*[J'P''6^,]FK%\7_\`(LW?_`/_`$-:XX?$
MCJG\+/,Z]9T7_D"6'_7O'_Z"*Z<1LCGH;LNT5R'4<[=?\?4W^^W\ZMV]J]^3
M/<2-CH,#D_3_`#ZUW3DHQ4CY/#TI5Z\J5[)N[^7_``Y-)I,>S]U(P;_:Y%5+
M.Y:TG,<A(3.''7!]:B,O:Q:>YU5:"P%:%2#]WK^II:E_QXR?A_,55T;_`);?
M\!_K6<?X+.NM_P`C&GZ?_)$M_?&!O*BQOQDD]O\`Z]5;/3O/C$LCX0]`O6KC
M^[AS=685T\=BO8WM&/\`P+EB328]G[J1@W^UR*J6UW+:2>6^2BDAE]/I3C+V
ML6F9UJ+RZK&I3=T]S:5@Z!E.0PR#3JY#Z%--7044#*6KWMO8:;--=!&3:5$;
M])"1POXUY-77AT[-G+7>J1>T743I>IPW6T,JG#@J"=IZX]#C_.,UZI#*EQ!'
M-$VZ.10ZG&,@C(J<1'5,J@]&B2BN8Z#F/'W_`"!(?^OA?_06K@*[J'P''6^,
M]FK%\7_\BS=_\`_]#6N.'Q(ZI_"SS.O6=%_Y`EA_U[Q_^@BNG$;(YZ&[+M%<
MAU'.W7_'U-_OM_.M^)/+B1,YVJ!FNFN_=1X>5Q_>U7_6['UBZLH6[!`Y903_
M`"_I44/C.C-DGA_FBW<-OT?=NW$JN3G/.146C?\`+;_@/]:O_EW+U,6[XVD_
M[OZ,J3-]JOC@@!W"@@=N@-;]*OHHHK*WSRJU.[_S_P`PK(UB,+,D@Q\PP>/3
M_P#74T'[YOFD>;#-]K?Y%[3V+6418Y."/R.*LUG/XF=6&;=&#?9?D%%2;GF_
MBS6CJ=^887/V6`E5`8$.PSEN/T]OJ:I:#I9U?4TMBQ6,`O(RXR%'IGW('XUW
MKW('"_?F5]2LGT[4)[20Y:)L`_WAU!_$8-=7X%U<L&TN9A\H+P<`=\LOOUS^
M=*JN:G<JF^6=CLJ*X3L.8\??\@2'_KX7_P!!:N`KNH?`<=;XSV:L7Q?_`,BS
M=_\``/\`T-:XX?$CJG\+/,Z]9T7_`)`EA_U[Q_\`H(KIQ&R.>ANR[17(=1SM
MU_Q]3?[[?SKHJZ:^T3Q<J_B5?5?J%8VK_P#'TO\`N#^9J*'QF^:_[N_5%F90
MNC`*,#:I_,@U'HW_`"V_X#_6K_Y=R]3G22QE%+^7]&4E`@O0&;B.3DX]#70T
MJ^MF5E%HJ<.S"LK66!>)<\@$D?7_`/544?C1TYFTL++Y?F6]-_X\8_Q_F:M5
M$_B9T87^!#T7Y!7.^+]:.FV0MK=RMU<#AE8`QKW/KSR!^//%.G'FDD:U)<L6
MSSNO3O#&D'2=,"2J!<RG?+@@X]%S[#Z\DUTXB5HV.>@KRN97CO3/-MH]1C'S
M0XCD_P!TG@]>Q/I_%[5Q,,KV\\<T3;9(V#J<9P0<BJHN\+$U5:=SU31=175-
M,ANAC>1B11_"PZCJ<>H]B*OUQ25FT=D7=7.8\??\@2'_`*^%_P#06K@*[:'P
M')6^,]FK%\7_`/(LW?\`P#_T-:XX?$CJG\+/,ZUH?$VKV\$<,5WMCC4(H\M#
M@`8':O0E!2W.&,G'8?\`\)7K?_/[_P"0D_PH_P"$KUO_`)_?_(2?X5'L8=B_
M:S[G16DDES;0RR$O+*BLQ`ZDCT%;5EJ$7DK'*0C+A0>Q%*K#FC9=#Q<#B(T*
M\G/9WU+$M_;Q#_6!SZ)S_P#6K)C5[Z\^;JQRQ'85G2BX)R9T8^O#$SA0IN^N
MO]?>:NI?\>,GX?S%5=&_Y;?\!_K41_@LZ*W_`",:?I_\D,U6V82F=02C8W>Q
MJ>TU)'0+.P5^F<<'_"K<?:4TUNC&%583&3C4TC+7^OQ18DO;>,9,JMZ!>:QY
M'DO;K@<N<`=<"BC!QO*1.98F-;EH4G?7_AC=B3RXD3.=J@9I]<S=V>[&/+%+
ML%8%_P"$[+4+V6ZN+BZ,DAR=K*`.P`^7T`JH3<'="G!35F)9^#]-L[N*Y62X
M=HF#JKN,9'3H!WKH*)S<W=A""@K(CFB2X@DAE7='(I1AG&01@USG_"#:9_SW
MN_\`OM?_`(FG"HX;"G34]S2T?0;;1GE:UFG82@!ED*D<=#P`>Y_.M6IE)R=V
M5&/*K(H:OI4&L6JV]R\BHKAP8R`<X([@^M8__"#:9_SWN_\`OM?_`(FKA5E%
M61$J2D[LZ>JNI6,6I6,EI.SK')C)0@'@@]_I6:=G<T:NK&%_P@VF?\][O_OM
M?_B:/^$&TS_GO=_]]K_\36WUB1C["(?\(-IG_/>[_P"^U_\`B:/^$&TS_GO=
M_P#?:_\`Q-'UB0>PB:]KI%O:K"L;RD1!0NXCG'KQ4EQIT,SL^61CZ=,^M+V\
MKW.1Y91<'"[U=R%-(0'YY6(]ABKL,$4`(B0+GK14JN>G0>$RZGAWS-WD+/$L
M\31L2`WI4=K:1VN[RRQW8SN-0IM1Y3IEAH2K*N]UIY=?\R<@,""`0>"#5&32
MH6R8V9#V'4"G"HX;&>+P<,2O>T:V8Q-(0'YY6(]ABKL4$4(_=QJO;/?\ZJI5
M<]#+"9=3P[YGJR6BL3T0HH`**`"B@`HH`**`"B@`HH`**`"B@`HH`**`"B@`
'HH`**`/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
